Vanadium compounds: Biological actions and potential as pharmacological agents

Trends in Endocrinology and Metabolism

Volumn 8, Issue 2, 1997, Pages 51-58

  Tsiani, E ^a,b   Fantus, I G ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; PHOSPHATE; PROTEIN TYROSINE PHOSPHATASE; VANADATE SODIUM; VANADIC ACID; VANADIUM DERIVATIVE; VANADYL SULFATE;

BLOOD TOXICITY; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ACCUMULATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOUSE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

EID: 0030937116     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(96)00262-7     Document Type: Review

References (83)

1. Ahmad F, Considine RV, Goldstein BJ Increased abundance of the receptor-type protein-tyrosine phosphatase LAR accounts for the elevated insulin receptor dephosphorylating activity in adipose tissue of obese human subjects. J Clin Invest. 95:1995;2806-2812.
2. cdc13 protein kinase. Anticancer Res. 12:1992;873-880.
3. Bosch F, Arino J, Gomez-Foix AM, Guinovart JJ Glycogenolytic noninsulin-like effects of vanadate on rat hepatocyte glycogen synthase and phosphorylase. J Biol Chem. 262:1987;218-222.
4. Brichard SM, Henquin J-C The role of vanadium in the management of diabetes. Trends Pharmacol Sci. 16:1995;265-270.
5. Brichard SM, Ongemba LN, Henquin JC Oral vanadate decreases muscle insulin resistance in obese fa/fa rats. Diabetologia. 35:1992;522-527.
6. v-src kinase activity by vanadate in intact cells accompanies a new phosphorylation state of the enzyme. J Biol Chem. 259:1984;9580-9686.
7. Brownsey RW, Dong GW Evidence for selective effects of vanadium on adipose cell metabolism involving actions on cAMP-dependent protein kinase. Mol Cell Biochem. 153:1995;131-137.
8. Bruck R, Prigozin H, Krepel Z, Rotenberg P, Shecter Y, Bar-Meir S Vanadate inhibits glucose output from isolated perfused rat liver. Hepatology. 14:1991;540-544.
9. Carey JD, Azevedo JL, Morris PG, Pories WJ, Dohm GL Okadaic acid, vanadate, and phenylarsine oxide stimulate 2-deoxyglucose transport in insulin-resistant human skeletal muscle. Diabetes. 44:1995;682-688.
10. Cheatham B, Kahn CR Insulin action and the insulin signaling network. Endocr Rev. 16:1995;117-142.
11. Chen YX, Yang DC, Brown AB, Jeng Y, Tatoyan A, Chan TM Activation of a membrane-associated phosphatidylinositol kinase through tyrosine-protein phosphorylation by naphthoquinones and orthovanadate. Arch Biochem Biophys. 283:1990;184-192.
12. Clark AS, Fagan JM, Mitch WE Selectivity of insulin-like actions of vanadate on glucose and protein metabolism in skeletal muscle. Biochem J. 232:1985;273-276.
13. Cohen N, Halberstam M, Shlimovich M, Chang CJ, Shamoon H, Rossetti L Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest. 95:1995;2501-2509.
14. Crans DC Aqueous chemistry of labile oxovanadates: relevance to biological studies. Comments Inorganic Chem. 16:1994;1-33.
15. Crans DC, Mahroof-Tahir M, Keramidas AD Vanadium chemistry and biochemistry of relevance for use of vanadium compounds as anti-diabetic agents. Mol Cell Biochem. 153:1995;17-24.
16. Cruz TF, Morgan A, Min W In vitro and in vivo antineoplastic effects of orthovanadate. Mol Cell Biochem. 153:1995;161-166.
17. Djordjevic C: 1995: Antitumor activity of vanadium compounds. In Sigel H, Sigel A, ed. Metal Ions in Biological Systems. New York, Marcel Dekker, 31:595-616.
18. Domingo JL, Gomez M, Sanchez OJ, Llobet JM, Keen CL Relationship between reduction in food intake and amelioration of hyperglycemia by oral vanadate in STZ-induced diabetic rats. Diabetes. 43:1994;1267.
19. Domingo JL, Gomez M, Sanchez OJ, Llobet JM, Keen CL Toxicology of vanadium compounds in diabetic rats: the action of chelating agents on vanadium accumulation. Mol Cell Biochem. 153:1995;233-240.
20. D'Onofrio F, Le MQ, Chiasson J-L, Srivastava AK Activation of mitogen-activated protein (MAP) kinases by vanadate is independent of insulin receptor autophosphorylation. FEBS Lett. 340:1994;269-275.
21. +)-ATPase inhibitor. J Biol Chem. 255:1980;5306-5312.
22. Elberg G, Li J, Shechter Y Vanadium activates or inhibits receptor and non-receptor protein tyrosine kinases in cell-free experiments, depending on its oxidation state: possible role of endogenous vanadium in controlling cellular protein tyrosine kinase activity. J Biol Chem. 269:1994;9521-9527.
23. Eriksson JW, Lonnorth P, Smith U Vanadate increases cell surface insulin binding and improves insulin sensitivity in both normal and insulin-resistant rat adipocytes. Diabetologia. 35:1992;510-516.
24. Fantus IG, Deragon G, Lai R, Tang S Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling. Mol Cell Biochem. 153:1995;103-112.
25. Fantus IG, Kadota S, Deragon G, Foster B, Posner BI Pervanadate [peroxide(s) of vanadate] mimics insulin action in rat adipocytes via activation of the insulin receptor tyrosine kinase. Biochemistry. 28:1989;8864-8871.
26. Fantus IG, Ahmad F, Deragon G Vanadate augments insulin binding and prolongs insulin action in rat adipocytes. Endocrinology. 127:1990;2716-2725.
27. Fantus IG, Ahmad F, Deragon G Vanadate augments insulin-stimulated insulin receptor kinase activity and prolongs insulin action in rat adipocytes: evidence for transduction of amplitude of signaling into duration of response. Diabetes. 43:1994;375-383.
28. Fantus IG, George R, Tang S, Chong P, Poznansky MJ The insulin-mimetic agent vanadate promotes receptor endocytosis and inhibits intracellular ligand-receptor degradation by a mechanism distinct from the lysosomotropic agents. Diabetes. 45:1996;1084-1093.
29. Faure R, Vincent M, Dufour M, Shaver A, Posner BI Arrest at the G2/M transition of the cell cycle by protein-tyrosine phosphatase inhibition: studies on a neuronal and a glial cell line. J Cell Biochem. 59:1995;389-401.
30. Feldman RA, Lowy DR, Vass WC Selective potentiation of C-fps/fes transforming activity by a phosphatase inhibitor. Oncogene Res. 5:1990;187-197.
31. Goldine AB, Simonson DC, Folli F, Patti M-E, Kahn CR In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Mol Cell Biochem. 153:1995;217-231.
32. Gresser MJ, Tracey AS: 1990. Vanadates as phosphate analogs in biochemistry. In Chasteen ND, ed. Vanadium in Biological Systems. Dordrecht, Kluwer Academic, pp 63-79.
33. Grinstein S, Furuya W, Lu DJ, Mills BG Vanadate stimulates oxygen consumption and tyrosine phosphorylation in electropermeabilized human neutrophils. J Biol Chem. 265:1990;318-327.
34. Hajjar JJ, Dobish MP, Tomicic TK Effect of chronic vanadate ingestion on amino acid and water absorption in rat intestine. Arch Toxicol. 63:1989;29-33.
35. Halberstam M, Cohen N, Shlimovich P, Rossetti L, Shamoon H Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes. 45:1996;659-666.
36. Hamaguchi T, Sudo T, Osada H RK-682, a potent inhibitor of tyrosine phosphatase arrested the mammalian cell cycle progression at G1 phase. FEBS Lett. 372:1995;54-58.
37. Hamel FG, Duckworth WC The relationship between insulin and vanadium metabolism in insulin target tissues. Mol Cell Biochem. 153:1995;95-102.
38. Hanauske U, Hanauske A-R, Marshall MH, Muggia VA, Von Hoff DD Biphasic effect of vanadium salts on in vitro tumor colony growth. Intern J Cell Cloning. 5:1987;170-178.
39. Haqu SJ, Flati V, Deb A, Williams BRG Role of protein-tyrosine phosphatases in stat 1α-mediated cell signaling. J Biol Chem. 270:1995;25,709-25,714.
40. Heyliger CE, Tahiliani AG, McNeil JH Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science. 227:1985;1474-1477.
41. Hunter T 3 thousand and one protein kinases. Cell. 50:1987;823-829.
42. Ida M, Imai K, Hashimoto S, Kawashima H Pervanadate stimulation of wortmannin-sensitive and -resistant 2-deoxyglucose transport in adipocytes. Biochem Pharmacol. 51:1996;1061-1067.
43. Jackson TK, Salhanick AI, Sparks JD, Sparks CE, Bolognino M, Amatruda JM Insulin-mimetic effects of vanadate in primary cultures of rat hepatocytes. Diabetes. 37:1988;1234-1240.
44. Kadota S, Fantus IG, Deragon G, Guyda HJ, Hersh B, Posner BI Peroxide(s) of vanadium: a novel and potent insulin-mimetic agent which activates the insulin receptor kinase. Biochem Biophys Res Commun. 147:1987;259-266.
45. Kahn CR Insulin resistance, insulin insensitivity, and insulin unresponsiveness: a necessary distinction. Metabolism. 27:1978;1893-1902.
46. Klarlund JK Transformation of cells by an inhibitor of phosphatases acting on phosphotyrosine proteins. Cell. 41:1985;707-717.
47. Kroder G, Bossenmaier B, Kellerer Met al. Tumor necrosis factor-α- and hyperglycemia-induced insulin resistance: evidence for different mechanisms and different effects on insulin signaling. J Clin Invest. 97:1996;1471-1477.
48. Leonard A, Gerber GB Mutagenicity, carcinogenicity and teratogenicity of vanadium compounds. Mutat Res. 317:1994;81-88.
49. Macara IG, Kustin K, Cantley LC Jr. Glutathione reduces cytoplasmic vanadate: Mechanism and physiological implications. Biochim Biophys Acta. 62:1980;95-106.
50. +-dependent glucose transport in rat small intestine. Diabetes. 42:1993;1126-1132.
51. McNeill JH, Yuen VG, Hoveyda HR, Orvig C Bis(maltolato) oxo vanadium (IV) is a potent insulin mimic. J Med Chem. 35:1992;1489-1491.
52. McNeill JH, Battell M, Cam M, Dai S, Thompson K, Yuen V Oral vanadium and lowering of blood glucose. Diabetes. 43:1994;1268.
53. Meyerovitch J, Shechter Y, Amir S Vanadate stimulates in vivo glucose uptake in brain and arrests food intake and body weight gain in rats. Physiol Behav. 45:1989;1113-1116.
54. Meyerovitch J, Rothenberg P, Schechter Y, Bonner-Weir S, Kahn CR Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J Clin Invest. 87:1991;1286-1294.
55. Milarski KL, Saltiel AR Expression of catalytically inactive syp phosphatase in 3T3 cells blocks stimulation of mitogen-activated protein kinase by insulin. J Biol Chem. 267:1994;21,239-21,243.
56. Munoz P, Guma A, Camps Met al. Vanadate stimulates system A amino acid transport activity in skeletal muscle. J Biol Chem. 267:1992;10,281-10,388.
57. Nechay BR, Nanninga LB, Nechay PSEet al. Role of vanadium in biology. Fed Proc. 45:1986;123-132.
58. Nielsen FH: 1995. Vanadium in mammalian physiology and nutrition. In Sigel H, Sigel A, Biological systems, New eds. Metal Ions in Biological Systems. New York, Marcel Dekker, 31:543-574.
59. Orvig C, Thompson KH, Battell M, McNeill JH: 1995. Vanadium compounds as insulin mimics. In Sigel H, Sigel A, eds. Metal Ions in Biological Systems. New York, Marcel Dekker, 31:575-594.
60. Pederson RA, Ramanadham S, Buchan AMJ, McNeill JH Long-term effects of vanadyl treatment on streptozotocin-induced diabetes in rats. Diabetes. 38:1989;1390-1395.
61. Posner BI, Shaver A, Fantus IG: 1990. Insulin mimetic agents: vanadium and peroxovanadium compounds. In Bailey CJ, Flatt PR, ed. New Antidiabetic Drugs. London, Smith-Gordon, pp 107-118.
62. Posner BI, Faure R, Burgess JWet al. Peroxovanadium compounds: a new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J Biol Chem. 269:1994;4596-4604.
63. Quon MJ, Butte AJ, Taylor SI Insulin signal transduction pathways. Trends Endocrinol Metab. 5:1994;369-376.
64. Roupas P, Herington AC Postreceptor signaling mechanisms for growth hormone. Trends Endocrinol Metab. 5:1994;154-158.
65. Schulz LO Suppression of the hepatic glucose-6-phosphatase system in diabetic rats by vanadate. Ann Nutr Metab. 32:1988;289-296.
66. Schwabe U, Puckstein C, Hammerman H, Sochtig E Activation of adenylate cyclase by vanadate. Nature. 277:1979;143-145.
67. Schwartz MW, Figlewicz DP, Baskin DG, Woods SC, Porte D Jr. Insulin in the brain: a hormonal regulator of energy balance. Endocr Rev. 13:1992;387-414.
68. Shaver A, Ng JB, Hall DA, Posner BI The chemistry of peroxovanadium compounds. Mol Cell Biochem. 153:1995;5-15.
69. Shechter Y Insulin mimetic effects of vanadate: possible implications for future treatment of diabetes. Diabetes. 39:1990;1-5.
70. Shechter Y, Karlish SJD Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions. Nature. 284:1980;556-558.
71. Shisheva A, Shechter Y Quercetin selectively inhibits insulin receptor function in vitro and the bioresponses of insulin and insulinomimetic agents in rat adipocytes. Biochemistry. 31:1992;8059-8063.
72. Shisheva A, Shechter Y Role of cytosolic tyrosine kinase in mediating insulin-like actions of vanadate in rat adipocytes. J Biol Chem. 268:1993;6463-6469.
73. Stankiewicz PJ, Tracey AS: 1995. Stimulation of enzyme activity by oxovanadium complexes. In Sigel H, Sigel A, eds. Metal Ions in Biological Systems. New York, Marcel Dekker, 31: 249-286b.
74. Stankiewicz PJ, Tracey AS, Crans DC: 1995. Inhibition of phosphate-metabolizing enzymes by oxovanadium complexes. In Sigel H, Sigel A, eds. Metal Ions in Biological Systems. New York, Marcel Dekker, 31:287-324a.
75. Tolman EL, Barris E, Burns M, Pansini A, Partridge R Effects of vanadium on glucose metabolism in vitro. Life Sci. 25:1979;1159-1164.
76. Tsiani E, Abdullah N, Fantus IG The insulin-mimetic agents vanadate and pervanadate stimulate glucose but inhibit amino acid uptake. Am J Physiol. 272:1997;C156-C162.
77. Ullrich A, Bell JR, Chen EYet al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature. 313:1985;756-761.
78. Wang H, Scott RE Unique and selective mitogenic effects of vanadate on SV40-transformed cells. Mol Cell Biochem. 153:1995;59-67.
79. Waters SB, Pessin JE Insulin receptor substrate 1 and 2 (IRS1 and IRS2): what a tangled web we weave. Trends Cell Biol. 6:1996;1-4.
80. Williams G, Malabu U Reply to Domingo et al and McNeil et al. Diabetes. 43:1994;1269-1270.
81. Xiao S, Rose DW, Sasaoka Tet al. Syp (SH-PTP2) is a positive mediator of growth factor-stimulated mitogenic signal transduction. J Biol Chem. 269:1994;21,244-21,248.
82. Yale JF, Lachance D, Bevan AP, Vigeant C, Shaver A, Posner BI Hypoglycemic effects of peroxovanadium compounds in Sprague-Dawley and diabetic BB rats. Diabetes. 44:1995;1274-1279.
83. Yuen VG, Orvig C, McNeill JH Glucose lowering effects of a new vanadium complex, bis(maltolato) oxovanadium (IV). Can J Physiol Pharmacol. 71:1993;263-269.